Company Announcement No 53/2025Peberlyk 46200 AabenraaDenmarkTel +45 74 37 37 37Fax +45 74 37 35 36Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk4 November 2025 Transactions with shares in Sydbank by managers and closely associated persons Under Article 19 of the Market Abuse Regulation Sydbank makes public transactions with shares in the Bank conducted by managers and persons closely associated with them. Reference is made to the attached table showing detailed information about the transaction. Your ...

Core Insights - TG4050 demonstrates the ability to induce neoantigen-specific cytotoxic CD8+ T cell responses, which can target and eliminate tumor cells, potentially reducing the risk of cancer relapse [1][3][4] Company Overview - Transgene is a biotech company focused on developing virus-based immunotherapies for cancer treatment, with TG4050 being its lead asset [9][12] - TG4050 is an individualized therapeutic vaccine based on the myvac® platform, designed to stimulate the immune system to recognize and destroy tumor cells [10][12] Clinical Development - TG4050 is currently being evaluated in a Phase I/II clinical trial for patients with HPV-negative head and neck cancers, with the first immunogenicity data from the Phase II part expected in the second half of 2026 [14] - The trial includes a randomized study design, assessing the treatment benefits of TG4050 in patients at risk of relapse [14] Immunological Data - New immunological data presented at the SITC Annual Meeting confirm TG4050's mechanism of action and its potential for sustained prevention of cancer relapses [4][5] - CD8+ T cells induced by TG4050 exhibit an effector phenotype and persist for up to two years post-treatment, indicating long-term immune response capabilities [8][5] Collaboration and Technology - Transgene collaborates with NEC Corporation, leveraging NEC's AI-driven platform to enhance the development of individualized neoantigen therapeutic vaccines [5][12] - NEC's Neoantigen Prediction System utilizes advanced AI to identify and select the most immunogenic sequences for the vaccine [15][12]

PRESS RELEASE Global Bioenergies: postponement of the takeover offers review hearing to 24 November Evry, 04 November 2025 – 05:45 p.m: The hearing which was held yesterday at the Commercial Court of Evry concluded with the decision to postpone until 24 November 2025 the review of the offers to take over Global Bioenergies’ activities. The new deadline for submitting the offers has been set up on 12 November 2025. As a reminder, the company had initiated a pre-pack sale process on 03 June 2025 and the Evry ...

Nanterre, November 03rd, 2025 Disclosure of transactions in on shares from October 27th to October 31st,2025 Within the framework of the authorization granted by the General Meeting of VINCI SA of April 17th, 2025, to trade in its shares and in accordance with the regulations relating to share buybacks, VINCI SA (LEI:213800WFQ334R8UXUG83) declares the purchases of treasury shares below (FR0000125486), carried out from October 27th to October 31st,2025: I - Aggregate presentation by day and by market Issu ...

Core Insights - The deployment of the first intelligent humanoid robot, named Hoxo, in the nuclear sector represents a significant technological advancement for the industry [2][3] - This initiative aims to enhance industrial performance and safety by integrating robotics with human operations in challenging environments [4][5] Company Overview - Orano is a leading international operator in nuclear materials, focusing on innovative solutions to address global energy and health challenges, with a workforce of 18,000 employees [7] - Capgemini is an AI-powered global business and technology transformation partner, with nearly 60 years of experience and a workforce of 420,000 across more than 50 countries, reporting global revenues of €22.1 billion in 2024 [8] Technological Innovation - Hoxo is equipped with advanced AI and sensors for real-time perception, autonomous navigation, and interaction, designed to replicate human movements and assist teams in nuclear facilities [3][4] - The project combines robotics, AI, computer vision, and digital twins, redefining human-machine interaction in sensitive environments and pushing the boundaries of industrial automation [6]

French public limited company (société anonyme)with a share capital of €1,467,334,437.50Registered office : 1973, boulevard de la Défense92000 Nanterre – France552 037 806 RCS Nanterrewww.vinci.com DISCLOSUREOF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER OF VOTING RIGHTSAS OF 31 OCTOBER 2025 Total number of shares586,933,775Theoretical number of voting rights (including treasury stock)586,933,775Number of voting rights (excluding treasury stock)558,394,791 This disclosure is on VINCI web ...

Paris, 04 November 2025, 5:45pm Solid Q3 2025 performance, driven by higher volumes and margins across core energy distribution activities, amid lower oil prices.Strong operational execution more than offset adverse EUR/USD effects, confirming the strength of Rubis’s diversified business model.Energy Distribution: sustained volume growth in Retail & Marketing (+6%), with LPG unit margin increase in Europe and strong momentum in bitumen. Support & Services revenue lower than Q3 2024 (-17%), mostly driven by ...

Core Insights - NNIT experienced a slight improvement in organic growth of 0.3 percentage points in Q3 2025 despite ongoing market unrest, although revenue contracted by 2.9% compared to Q3 2024 [2][5] - The group operating profit excluding special items more than doubled to DKK 35.6 million, resulting in a margin of 8.2%, up from 3.9% in the same quarter last year, driven by operational efficiency improvements [2][5] - The company anticipates continued momentum in profitability and revenue growth, supported by a focus on repeatable solutions and advancements in AI [2][5] Financial Performance - Q3 2025 revenue was DKK 431.6 million, down from DKK 444.7 million in Q3 2024, reflecting a negative revenue growth of 2.9% and organic growth of -1.4% [3][5] - Group operating profit excluding special items for the first nine months of 2025 was DKK 76.5 million, compared to DKK 73.4 million in the same period of 2024, with a margin of 5.6% [3][5] - Special items in Q3 2025 amounted to DKK 7.9 million, with total group operating profit including special items at DKK 27.7 million [3][5] Strategic Focus - NNIT is enhancing its operational model to improve efficiency, achieving a utilization improvement of approximately 4 percentage points while maintaining high customer satisfaction at 4.5 [5] - The company is broadening its market engagement by targeting lower-tier customers and maintaining a solid order entry, which is a positive indicator for future performance [5] - NNIT maintains its full-year financial outlook for 2025, expecting organic growth at the lower end of 0 to 5% and a group operating profit margin excluding special items in the lower end of 7 to 9% [5]

JCDecaux Dicon receives “Excellence in Long-Term Partnership” award at OneDXB Airport Excellence Awards, celebrating 17 years of innovation and collaboration with Dubai Airports Paris, November 4th, 2025 – JCDecaux SE (Euronext Paris: DEC), the number one outdoor advertising company worldwide, present in 157 airports across the world, proudly announced that its Dubai-based subsidiary, JCDecaux Dicon, has been honored with the “Excellence in Long-Term Partnership” award at the prestigious “OneDXB Airport ...

Aspo Plc ANNOUNCEMENT 4.11.2025 Aspo Plc: Share repurchase 4.11.2025 In the Helsinki Stock Exchange Trade date 4.11.2025 Bourse trade Buy Share ASPO Amount 2 500SharesAverage price/ share 6,5120EURTotal cost 16 280,00EUR Aspo Plc now holds a t ...